Skip to content

Study · Not a test of the peptide alone · 2023

4 results

NAD+ precursor supplementation prevents mtRNA/RIG-I-dependent inflammation during kidney injury.

Doke T, Mukherjee S, Mukhi D, Dhillon P, Abedini A, Davis JG, Chellappa K, Chen B, Baur JA, Susztak K

Nature metabolism13 Mar 2023Cited by 105 (Europe PMC)

PMID36914909 (opens in a new tab)PMCIDPMC10230446 (opens in a new tab)DOI10.1038/s42255-023-00761-7 (opens in a new tab)PepBankPUB-36914909
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

  1. 01AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In male mice with kidney injury, supplemental nicotinamide riboside or NMN restored NAD levels without separate precursor results.

    In plain wordsIn male mice with kidney injury, nicotinamide riboside or NMN restored NAD levels, without separate results for each precursor.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseNAD restoration
    Study

    mousen: not reported in source

    male mice with cisplatin- or ischaemia-reperfusion-induced kidney injury
    Outcome group
    Receptor activity and mechanism · Kidney and urinary

    Source sentences

    Summary
    Furthermore using models of cisplatin- or ischaemia-reperfusion induced kidney injury in male mice we observed NAD+ depletion Supplemental nicotinamide riboside or nicotinamide mononucleotide restores NAD+ levels and improved kidney function.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

  2. 02AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In male mice with kidney injury, supplemental nicotinamide riboside or NMN improved kidney function without separate precursor results.

    In plain wordsIn male mice with kidney injury, nicotinamide riboside or NMN improved kidney function, without separate results for each precursor.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseKidney function
    Study

    mousen: not reported in source

    male mice with cisplatin- or ischaemia-reperfusion-induced kidney injury
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Furthermore using models of cisplatin- or ischaemia-reperfusion induced kidney injury in male mice we observed NAD+ depletion Supplemental nicotinamide riboside or nicotinamide mononucleotide restores NAD+ levels and improved kidney function.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

  3. 03AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Mechanism

    In cisplatin injury experiments, NAD restoration ameliorated cytosolic mitochondrial RNA leakage, without a precursor-specific result.

    In plain wordsIn mice with cisplatin injury, NAD restoration reduced mitochondrial RNA leakage, without a separate NMN result.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseCytosolic mtRNA leakage
    Study

    mousen: not reported in source

    male mice with cisplatin- or ischaemia-reperfusion-induced kidney injury
    Outcome group
    Receptor activity and mechanism · Kidney and urinary

    Source sentences

    Summary
    We find that cisplatin exposure causes cytosolic leakage of mitochondrial RNA (mtRNA) and activation of the cytosolic pattern recognition receptor retinoic acid-inducible gene I (RIG-I), both of which can be ameliorated by restoring NAD+.
    1 context sentence
    Summary · context
    Furthermore using models of cisplatin- or ischaemia-reperfusion induced kidney injury in male mice we observed NAD+ depletion Supplemental nicotinamide riboside or nicotinamide mononucleotide restores NAD+ levels and improved kidney function.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

  4. 04AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Mechanism

    In cisplatin injury experiments, NAD restoration ameliorated RIG-I activation, without a precursor-specific result.

    In plain wordsIn mice with cisplatin injury, NAD restoration reduced RIG-I activation, without a separate NMN result.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseRIG-I activation
    Study

    mousen: not reported in source

    male mice with cisplatin- or ischaemia-reperfusion-induced kidney injury
    Outcome group
    Receptor activity and mechanism · Kidney and urinary

    Source sentences

    Summary
    We find that cisplatin exposure causes cytosolic leakage of mitochondrial RNA (mtRNA) and activation of the cytosolic pattern recognition receptor retinoic acid-inducible gene I (RIG-I), both of which can be ameliorated by restoring NAD+.
    1 context sentence
    Summary · context
    Furthermore using models of cisplatin- or ischaemia-reperfusion induced kidney injury in male mice we observed NAD+ depletion Supplemental nicotinamide riboside or nicotinamide mononucleotide restores NAD+ levels and improved kidney function.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.